Gastrointestinal Tolerance Clinical Trial
Official title:
Tolerance of Infants Fed a Hydrolyzed Infant Formula
NCT number | NCT05369494 |
Other study ID # | AL49 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 7, 2022 |
Est. completion date | November 18, 2023 |
Verified date | April 2024 |
Source | Abbott Nutrition |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this non-randomized, multi-center study is to evaluate the growth, tolerance and compliance of an extensively hydrolyzed infant formula in an intended use population of infants.
Status | Completed |
Enrollment | 33 |
Est. completion date | November 18, 2023 |
Est. primary completion date | June 23, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Days to 90 Days |
Eligibility | Inclusion Criteria: - Infant is 0 to 90 days of age at enrollment. - Formula-fed Infant who is either experiencing persistent feeding intolerance, symptoms of suspected food protein allergy or currently consuming an extensively hydrolyzed formula (EHF) for symptoms of suspected food protein allergy, persistent feeding intolerance symptoms or other conditions where EHF is deemed an appropriate feeding by their health care professional - Parent(s) of infants confirm their intention not to administer prescription medications, OTC medications, home remedies, prebiotics, probiotics, herbal preparations or rehydration fluids that might affect GI tolerance, unless their infants are currently consuming and have been directed by their healthcare professional to continue their use during the study - Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study. - Parent(s) confirm their intention not to administer solid foods or juices to their infant from enrollment through the duration of the study - Parent(s) confirm their intention not to administer vitamin or mineral supplements (with the exception of Vitamin D supplements) to their infant from enrollment through the duration of the study, unless instructed otherwise by their healthcare professional - Infant's parent(s) or a LAR has voluntarily signed and dated an informed consent form (ICF) approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study Exclusion Criteria: - An adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on growth, and/or development - Awareness of a positive drug screen in the mother or participant - Suspected maternal substance abuse including alcohol - Participation in another study that has not been approved as a concomitant study by AN - Participant is receiving oral or inhaled steroids - Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent - Participant has received an amino acid-based formula |
Country | Name | City | State |
---|---|---|---|
United States | Meridian Clinical Research 3357 | Charleston | South Carolina |
United States | Javara Inc. | Fayetteville | Georgia |
United States | Gentle Pediatrics | Houston | Texas |
United States | Meridian Clinical Research 3259 | Macon | Georgia |
United States | AdventHealth Medical Group Pediatrics | Orange City | Florida |
United States | Springs Medical Research | Owensboro | Kentucky |
United States | Meridian Clinical Research, LLC | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Abbott Nutrition |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Parent Perspectives Questionnaire | Parent completed questionnaire; 4, 5-point Likert scale questions, scaled from negative to positive with higher scores indicating better perception | Study Day1 to Study Day 28 | |
Other | Formula Satisfaction Questionnaire | Parent completed questionnaire; 13 questions of up to 5 categories, scaled from positive to negative | Study Day1 to Study Day 28 | |
Other | Infant Feeding and Stool Patterns Questionnaire | Parent completed questionnaire; 16, 5-point Likert scale questions, scaled from always to never | Study Day1 to Study Day 28 | |
Other | Health Care Utilization | Number of Visits | Study Day1 to Study Day 28 | |
Other | Adverse Events | Parent reported adverse events | Study Day1 to Study Day 28 | |
Primary | Weight Maintenance | Change in weight for age z-score | Study Day1 to Study Day 28 | |
Secondary | Gastrointestinal Tolerance | Parent completed diary | Study Day1 to Study Day 28 | |
Secondary | Weight | Weight gain per day in grams | Study Day1 to Study Day 28 | |
Secondary | Length | Length gain per day in cm | Study Day1 to Study Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04100460 -
A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).
|
N/A | |
Completed |
NCT00977964 -
Tolerance of Healthy Term Infants Fed Infant Formulas #3
|
Phase 3 | |
Not yet recruiting |
NCT05827198 -
Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies
|
N/A | |
Completed |
NCT03945149 -
A Clinical Trial to Evaluate the Chronic Safety and Tolerance of Turmipure Gold™ in Healthy Subjects
|
N/A | |
Completed |
NCT03539146 -
Gastrointestinal Tolerance, Satiation and Sensory Acceptance of Yogurts Containing Dietary Fiber and Coffee Cascara Extract
|
N/A | |
Completed |
NCT02757924 -
Behavior of Infants Fed Formula Supplemented With Prebiotics
|
N/A | |
Completed |
NCT05213494 -
The Effects of Soluble Corn Fiber on Gastrointestinal Tolerance and Fecal Microbiome in Healthy Children
|
N/A | |
Completed |
NCT05051202 -
A Study Assessing the Tolerable Upper Intake Level and Safety of Sugars From Fiber
|
N/A | |
Completed |
NCT01902212 -
Evaluation of an Oral Nutrition Supplement
|
N/A | |
Completed |
NCT03597113 -
Evaluation of Infants Fed an Extensively Hydrolyzed Hypo Allergenic Infant Formula
|
||
Completed |
NCT04745455 -
Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics.
|
N/A | |
Completed |
NCT02322138 -
Gastrointestinal Tolerance of Infant Formula
|
N/A | |
Completed |
NCT04945083 -
Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for Malnutrition
|
N/A | |
Completed |
NCT03648255 -
TolerUp Enteral Feeding Protocol
|
||
Completed |
NCT03769012 -
Ability of Beta-glucan Supplementation to Augment Immune Function
|
N/A | |
Completed |
NCT02456831 -
Soy Formula Feedings in Healthy, Term Infants
|
N/A | |
Completed |
NCT03628183 -
Tolerance of Infants Fed a Hydrolysate Formula
|
N/A | |
Completed |
NCT02456805 -
Alternate Formula Feedings in Formula Intolerant Infants
|
N/A | |
Recruiting |
NCT04966299 -
Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents
|
N/A | |
Completed |
NCT02746016 -
Effect of Formula on Infant Behavior
|
N/A |